Speciality Medicines Ipo
Speciality Medicines IPO Review & Key Points
Review: Neutral
IPO Lead Managers aka Merchant Bankers
Unicon Capital Services Pvt. Ltd.
| Name of the Company | Face Value (₹) | EPS basic (₹) | EPS Diluted (₹) | RONW (%) | P/E Ratio | NAV (₹) |
| Powerica Limited | 5 | 15.26 | 15.26 | 15.37 % | 24.45 | 99.76 |
| Listed Peers | ||||||
| Cummins India Limited | 2 | 72.15 | 72.15 | 26.45% | 64.13 | 272.78 |
| Kirloskar Oil Engines Limited | 2 | 33.71 | 33.60 | 15.85% | 43.24 | 212.60 |
| NTPC Green Energy Limited | 10 | 0.67 | 0.67 | 2.58% | 129.40 | 21.88 |
| Acme Solar Holdings Limited | 2 | 4.55 | 4.53 | 5.59% | 50.74 | 74.54 |
| Adani Green Energy Limited | 10 | 8.37 | 8.37 | 11.90% | 101.53 | 76.62 |
| IPO Open Date | March 20, 2026 |
| IPO Close Date | March 24, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹117 to ₹124 Per Share |
| Issue Size | Approx ₹29.14 Crores |
| Fresh Issue | Approx ₹29.14 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus |
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,48,000 |
| Retail Maximum | 2 | 2,000 | ₹2,48,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,72,000 |
| S-HNI Maximum | 8 | 8,000 | ₹9,92,000 |
| B-HNI Minimum | 9 | 9,000 | ₹11,16,000 |
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 2% |
| NII Shares Offered | – Shares | 49% |
| Retail Shares Offered | – Shares | 49% |
| IPO Open Date: | March 20, 2026 |
| IPO Close Date: | March 24, 2026 |
| Basis of Allotment: | March 25, 2026 |
| Refunds: | March 27, 2026 |
| Credit to Demat Account: | March 27, 2026 |
| IPO Listing Date: | March 30, 2026 |
| IPO Bidding Cut-off Time: | March 24, 2026 – 5 PM |
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 64,35,796 | 59.28% |
| Promoter Holding Post Issue | 87,85,796 | -% |
| Purpose | Crores |
| Setting up of the Research and Development (R&D) Centre | ₹13.31 |
| Product registration in the international markets | ₹2.89 |
| Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | ₹1.75 |
| To Meet Working Capital Requirements | ₹12.00 |
| General Corporate Purpose | ₹- |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2024 | ₹27.66 | ₹23.10 | ₹2.93 | ₹22.68 |
| 2025 | ₹58.54 | ₹49.85 | ₹8.61 | ₹39.98 |
| Oct 2025 | ₹36.93 | ₹30.80 | ₹6.06 | ₹45.57 |
| KPI | Values |
| ROE: | 37.85% |
| ROCE: | 33.39% |
| EBITDA Margin: | 15.60% |
| PAT Margin: | 14.77% |
| Debt to equity ratio: | 0.17 |
| Earning Per Share (EPS): | ₹14.10 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 28.42% |
| Net Asset Value (NAV): | ₹47.07 |
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Remus Pharmaceuticals Limited | 65.21 | 12.25 | 15.02% | 434.25 | 620.36 Cr. |
| Trident Lifeline Limited | 10.22 | 27.59 | 18.23% | 56.05 | 86.96 Cr. |
| Mono Pharmacare Limited | 1.75 | 13.87 | 9.90% | 17.66 | 168.34 Cr. |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹184.81 | ₹154.97 | ₹32.10 | ₹251.58 |
| 2024 | ₹206.45 | ₹175.85 | ₹34.44 | ₹339.25 |
| 2025 | ₹322.58 | ₹261.43 | ₹28.13 | ₹455.49 |
| Dec 2025 | ₹236.50 | ₹186.96 | ₹38.69 | ₹561.34 |